{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:28:54Z","timestamp":1787840934056,"version":"build-2784847793"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      A dinucleotide variant rs368234815 in interferon lambda 4 (\n                      <jats:italic toggle=\"yes\">IFNL4<\/jats:italic>\n                      ) gene was recently found to be associated with the hepatitis C virus (HCV) treatment response. This study aimed to assess the impact of\n                      <jats:italic toggle=\"yes\">IFNL4<\/jats:italic>\n                      rs368234815 polymorphism on treatment response to pegylated-IFN alpha (Peg-IFN-\u03b1) and ribavirin (RBV) in hemophilic patients with chronic hepatitis C (CHC).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      In this retrospective study, 92 hemophilic patients with CHC who were treated with Peg-IFN-\u03b1\/RBV were investigated. Single-nucleotide polymorphisms (SNPs) in\n                      <jats:italic toggle=\"yes\">IFNL<\/jats:italic>\n                      genomic region including rs368234815, rs12979860, and rs8099917 were analyzed by DNA sequencing.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Of the 92 patients, 63 (68.5%) achieved sustained virological response (SVR). Of the 43 patients with rs368234815 TT\/TT genotype, 36 (83.7%) achieved SVR, while in 49 patients with non-TT\/TT genotypes, 27 (55.1%) achieved SVR. Other pretreatment parameters predicted SVR were patients\u2019 body mass index, HCV genotype, rs12979860, and rs8099917 SNPs. In multivariate analysis, all above-mentioned parameters except rs8099917 remained as predictors of SVR.\n                      <jats:italic toggle=\"yes\">IFNL4<\/jats:italic>\n                      rs368234815 was a strong predictor of SVR; however, the prediction power of this SNP was the same as that of rs12979860 SNP in the patients of the current study.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      <jats:italic toggle=\"yes\">IFNL4<\/jats:italic>\n                      rs368234815 SNP can be considered for decision-making in the treatment of HCV-infected patients.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/1735-1995.189678","type":"journal-article","created":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T06:21:13Z","timestamp":1472710873000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["The interferon lambda 4 rs368234815 predicts treatment response to pegylated-interferon alpha and ribavirin in hemophilic patients with chronic hepatitis C"],"prefix":"10.4103","volume":"21","author":[{"given":"Maryam","family":"Keshvari","sequence":"first","affiliation":[{"name":"Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Moayed","family":"Alavian","sequence":"additional","affiliation":[{"name":"Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran"},{"name":"Middle East Liver Diseases Center, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bita","family":"Behnava","sequence":"additional","affiliation":[{"name":"Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran"},{"name":"Middle East Liver Diseases Center, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Pouryasin","sequence":"additional","affiliation":[{"name":"Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, Iran"},{"name":"Armin Pathobiology Laboratory, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidar","family":"Sharafi","sequence":"additional","affiliation":[{"name":"Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran"},{"name":"Middle East Liver Diseases Center, Tehran, Iran"},{"name":"Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2016,9,1]]},"reference":[{"key":"R1-20250827","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/474S2a","article-title":"Introduction: A smouldering public-health crisis","volume":"474","author":"Gravitz","year":"2011","journal-title":"Nature"},{"key":"R2-20250827","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","article-title":"Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence","volume":"57","author":"Mohd Hanafiah","year":"2013","journal-title":"Hepatology"},{"key":"R3-20250827","doi-asserted-by":"crossref","first-page":"958","DOI":"10.5812\/kowsar.1735143X.4151","article-title":"IL28B polymorphism, explanation for different responses to therapy in hepatitis C patients","volume":"11","author":"Sharafi","year":"2011","journal-title":"Hepat Mon"},{"key":"R4-20250827","doi-asserted-by":"crossref","first-page":"e22649","DOI":"10.5812\/hepatmon.22649","article-title":"The impact of IFNL4 rs12979860 polymorphism on spontaneous clearance of hepatitis C; a case-control study","volume":"14","author":"Sharafi","year":"2014","journal-title":"Hepat Mon"},{"key":"R5-20250827","doi-asserted-by":"crossref","first-page":"8935","DOI":"10.3748\/wjg.v21.i29.8935","article-title":"Interferon-lambda polymorphisms and response to pegylated interferon in Iranian hepatitis C patients","volume":"21","author":"Haj-Sheykholeslami","year":"2015","journal-title":"World J Gastroenterol"},{"key":"R6-20250827","first-page":"1062","article-title":"Interleukin-28B (rs12979860) gene variation and treatment outcome after peginterferon plus ribavirin therapy in patients with genotype 1 of hepatitis C virus","volume":"19","author":"Kalantari","year":"2014","journal-title":"J Res Med Sci"},{"key":"R7-20250827","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/ng.2521","article-title":"A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus","volume":"45","author":"Prokunina-Olsson","year":"2013","journal-title":"Nat Genet"},{"key":"R8-20250827","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/apt.12589","article-title":"Letter: The rs12979860 and ss469415590 polymorphisms of IFNL4 gene are in strong linkage disequilibrium in Caucasian patients with chronic hepatitis C","volume":"39","author":"Keshvari","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"R9-20250827","first-page":"190","article-title":"Development and validation of a simple, rapid and inexpensive PCR-RFLP method for genotyping of common IL28B polymorphisms: A useful pharmacogenetic tool for prediction of hepatitis C treatment response","volume":"12","author":"Sharafi","year":"2012","journal-title":"Hepat Mon"},{"key":"R10-20250827","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/liv.12464","article-title":"Can we include genetic variants with high linkage disequilibrium into a multiple logistic model?","volume":"34","author":"Keshvari","year":"2014","journal-title":"Liver Int"},{"key":"R11-20250827","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/apt.12547","article-title":"Polymorphisms of interferon-lambda4 and IL28B \u2013 Effects on treatment response to interferon\/ribavirin in patients with chronic hepatitis C","volume":"39","author":"St\u00e4ttermayer","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"R12-20250827","doi-asserted-by":"crossref","first-page":"e95515","DOI":"10.1371\/journal.pone.0095515","article-title":"IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against hepatitis C virus genotype 1 or 4 in Caucasians","volume":"9","author":"Real","year":"2014","journal-title":"PLoS One"},{"key":"R13-20250827","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1160\/TH13-11-897","article-title":"Interferon lambda 3 rs12979860 polymorphism in patients with haemophilia and HCV infection: A predictor of spontaneous viral clearance and sustained virological response","volume":"111","author":"Mancuso","year":"2014","journal-title":"Thromb Haemost"},{"key":"R14-20250827","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1365-2516.2012.02932.x","article-title":"Genetic polymorphism of IL28B in hepatitis C-infected haemophilia patients in Israel","volume":"19","author":"Maor","year":"2013","journal-title":"Haemophilia"},{"key":"R15-20250827","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/j.1478-3231.2010.02296.x","article-title":"Peginterferon alpha-2a and ribavirin treatment of patients with haemophilia and hepatitis C virus infection: A single-centre study of 367 cases","volume":"30","author":"Alavian","year":"2010","journal-title":"Liver Int"},{"issue":"Pt 6","key":"R16-20250827","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1099\/vir.0.060103-0","article-title":"IFNL4\/IL-28B haplotype structure and its impact on susceptibility to hepatitis C virus and treatment response in the Japanese population","volume":"95","author":"Ochi","year":"2014","journal-title":"J Gen Virol"},{"key":"R17-20250827","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/apt.12568","article-title":"The novel ss469415590 variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infection","volume":"39","author":"Covolo","year":"2014","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Journal of Research in Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01222967-201621000-00072","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:31:32Z","timestamp":1787837492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01222967-201621000-00072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.4103\/1735-1995.189678","relation":{},"ISSN":["1735-1995","1735-7136"],"issn-type":[{"value":"1735-1995","type":"print"},{"value":"1735-7136","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"2015-11-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-05-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}